TGF-β regulates sclerostin expression via the ECR5 enhancer

Bone

Volumn 50, Issue 3, 2012, Pages 663-669

  Loots, Gabriela G ^a,b   Keller, Hansjoerg ^c   Leupin, Olivier ^c   Murugesh, Deepa ^a   Collette, Nicole M ^a   Genetos, Damian C ^d  

^a LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bone; ECR5; Osteoblast; Sost; Transforming growth factor beta; Wnt

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXY 1 METHYLTETRALIN; ACTIVIN A; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA2; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA3; RNA; SCLEROSTIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; BONE GROWTH; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; MALE; MOUSE; NONHUMAN; OSTEOBLAST; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; TRANSCRIPTION REGULATION;

ACTIVINS; ANIMALS; BONE MORPHOGENETIC PROTEINS; CELL LINE; ENHANCER ELEMENTS, GENETIC; GENETIC MARKERS; MALE; MICE; OSTEOBLASTS; PARATHYROID HORMONE; PTERIDINES; RATS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84856973218     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.11.016     Document Type: Article

References (59)

1. Gong Y., Slee R.B., Fukai N., Rawadi G., Roman-Roman S., Reginato A.M., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001, 107:513-523.
2. Little R.D., Carulli J.P., Del Mastro R.G., Dupuis J., Osborne M., Folz C., et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002, 70:11-19.
3. Almeida M., Han L., Bellido T., Manolagas S.C., Kousteni S. Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem 2005, 280:41342-41351.
4. Bodine P.V., Billiard J., Moran R.A., Ponce-de-Leon H., McLarney S., Mangine A., et al. The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem 2005, 96:1212-1230.
5. Williams B.O., Insogna K.L. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone. J Bone Miner Res 2009, 24:171-178.
6. Choi H.Y., Dieckmann M., Herz J., Niemeier A. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS One 2009, 4:e7930.
7. Kato M., Patel M.S., Levasseur R., Lobov I., Chang B.H., Glass D.A., et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 2002, 157:303-314.
8. Leupin O., Piters E., Halleux C., Hu S., Kramer I., Morvan F., et al. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem 2011, 286:19489-19500.
9. Balemans W., Ebeling M., Patel N., Van Hul E., Olson P., Dioszegi M., et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001, 10:537-543.
10. Brunkow M.E., Gardner J.C., Van Ness J., Paeper B.W., Kovacevich B.R., Proll S., et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001, 68:577-589.
11. Balemans W., Patel N., Ebeling M., Van Hul E., Wuyts W., Lacza C., et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002, 39:91-97.
12. Kusu N., Laurikkala J., Imanishi M., Usui H., Konishi M., Miyake A., et al. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 2003, 278:24113-24117.
13. Loots G.G., Kneissel M., Keller H., Baptist M., Chang J., Collette N.M., et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in van Buchem disease. Genome Res 2005, 15:928-935.
14. Nakanishi R., Shimizu M., Mori M., Akiyama H., Okudaira S., Otsuki B., et al. Secreted frizzled-related protein 4 is a negative regulator of peak BMD in SAMP6 mice. J Bone Miner Res 2006, 21:1713-1721.
15. Bodine P.V., Zhao W., Kharode Y.P., Bex F.J., Lambert A.J., Goad M.B., et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol 2004, 18:1222-1237.
16. Leupin O., Kramer I., Collette N.M., Loots G.G., Natt F., Kneissel M., et al. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res 2007, 22:1957-1967.
17. Kanaan R.A., Kanaan L.A. Transforming growth factor beta1, bone connection. Med Sci Monit 2006, 12:RA164-RA169.
18. Santibanez J.F., Quintanilla M., Bernabeu C. TGF-beta/TGF-beta receptor system and its role in physiological and pathological conditions. Clin Sci 2011, 121:233-251.
19. Origuchi N., Ishidou Y., Nagamine T., Onishi T., Matsunaga S., Yoshida H., et al. The spatial and temporal immunolocalization of TGF-beta 1 and bone morphogenetic protein-2/-4 in phallic bone formation in inbred Sprague Dawley male rats. In Vivo 1998, 12:473-480.
20. Janssens K., ten Dijke P., Janssens S., Van Hul W. Transforming growth factor-beta1 to the bone. Endocr Rev 2005, 26:743-774.
21. Bonewald L.F., Dallas S.L. Role of active and latent transforming growth factor beta in bone formation. J Cell Biochem 1994, 55:350-357.
22. Sowa H., Kaji H., Iu M.F., Tsukamoto T., Sugimoto T., Chihara K. Parathyroid hormone-Smad3 axis exerts anti-apoptotic action and augments anabolic action of transforming growth factor beta in osteoblasts. J Biol Chem 2003, 278:52240-52252.
23. Pilbeam C.C., Kawaguchi H., Voznesensky O.S., Alander C.B., Raisz L.G. Regulation of inducible prostaglandin G/H synthase by interleukin-1, transforming growth factors-alpha and -beta, and prostaglandins in bone cells. Adv Exp Med Biol 1997, 400B:617-623.
24. Sutherland M.K., Geoghegan J.C., Yu C., Winkler D.G., Latham J.A. Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone 2004, 35:448-454.
25. Kamiya N., Ye L., Kobayashi T., Mochida Y., Yamauchi M., Kronenberg H.M., et al. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development 2008, 135:3801-3811.
26. Papanicolaou S.E., Phipps R.J., Fyhrie D.P., Genetos D.C. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells. Biorheology 2009, 46:389-399.
27. Kulkarni N.H., Halladay D.L., Miles R.R., Gilbert L.M., Frolik C.A., Galvin R.J., et al. Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 2005, 95:1178-1190.
28. Keller H., Kneissel M. SOST is a target gene for PTH in bone. Bone 2005, 37:148-158.
29. Genetos D.C., Yellowley C.E., Loots G.G. Prostaglandin E(2) signals through PTGER2 to regulate sclerostin expression. PLoS One 2011, 6:e17772.
30. Kamiya N., Ye L., Kobayashi T., Lucas D.J., Mochida Y., Yamauchi M., et al. Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass. J Bone Miner Res 2008, 23:2007-2017.
31. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
32. Yingling J.M., Blanchard K.L., Sawyer J.S. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004, 3:1011-1022.
33. Jinnin M., Ihn H., Tamaki K. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol 2006, 69:597-607.
34. Fickett J.W. Quantitative discrimination of MEF2 sites. Mol Cell Biol 1996, 16:437-441.
35. Dennler S., Itoh S., Vivien D., ten Dijke P., Huet S., Gauthier J.M. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998, 17:3091-3100.
36. Winkler D.G., Sutherland M.K., Geoghegan J.C., Yu C., Hayes T., Skonier J.E., et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003, 22:6267-6276.
37. Semenov M., Tamai K., He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 2005, 280:26770-26775.
38. Li X., Ominsky M.S., Warmington K.S., Morony S., Gong J., Cao J., et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009, 24:578-588.
39. Ominsky M.S., Vlasseros F., Jolette J., Smith S.Y., Stouch B., Doellgast G., et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010, 25:948-959.
40. van Bezooijen R.L., ten Dijke P., Papapoulos S.E., Lowik C.W. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 2005, 16:319-327.
41. Robey P.G., Young M.F., Flanders K.C., Roche N.S., Kondaiah P., Reddi A.H., et al. Osteoblasts synthesize and respond to transforming growth factor-type beta (TGF-beta) in vitro. J Cell Biol 1987, 105:457-463.
42. Seyedin S.M., Thompson A.Y., Bentz H., Rosen D.M., McPherson J.M., Conti A., et al. Cartilage-inducing factor-A. Apparent identity to transforming growth factor-beta. J Biol Chem 1986, 261:5693-5695.
43. Mundy G.R., Bonewald L.F. Role of TGF beta in bone remodeling. Ann N Y Acad Sci 1990, 593:91-97.
44. Sanford L.P., Ormsby I., Gittenberger-de Groot A.C., Sariola H., Friedman R., Boivin G.P., et al. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 1997, 124:2659-2670.
45. Hering S., Isken E., Knabbe C., Janott J., Jost C., Pommer A., et al. TGFbeta1 and TGFbeta2 mRNA and protein expression in human bone samples. Exp Clin Endocrinol Diabetes 2001, 109:217-226.
46. Alliston T., Choy L., Ducy P., Karsenty G., Derynck R. TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J 2001, 20:2254-2272.
47. Balooch G., Balooch M., Nalla R.K., Schilling S., Filvaroff E.H., Marshall G.W., et al. TGF-beta regulates the mechanical properties and composition of bone matrix. Proc Natl Acad Sci U S A 2005, 102:18813-18818.
48. Mohammad K.S., Chen C.G., Balooch G., Stebbins E., McKenna C.R., Davis H., et al. Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One 2009, 4:e5275.
49. de Gorter D.J., van Dinther M., Korchynskyi O., ten Dijke P. Biphasic effects of transforming growth factor beta on bone morphogenetic protein-induced osteoblast differentiation. J Bone Miner Res 2011, 26:1178-1187.
50. Jian H., Shen X., Liu I., Semenov M., He X., Wang X.F. Smad3-dependent nuclear translocation of beta-catenin is required for TGF-beta1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells. Genes Dev 2006, 20:666-674.
51. Maeda S., Hayashi M., Komiya S., Imamura T., Miyazono K. Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO J 2004, 23:552-563.
52. Atkins G.J., Rowe P.S., Lim H.P., Welldon K.J., Ormsby R., Wijenayaka A.R., et al. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res 2011, 26:1425-1436.
53. Quinn Z.A., Yang C.C., Wrana J.L., McDermott J.C. Smad proteins function as co-modulators for MEF2 transcriptional regulatory proteins. Nucleic Acids Res 2001, 29:732-742.
54. Ishikawa F., Miyoshi H., Nose K., Shibanuma M. Transcriptional induction of MMP-10 by TGF-beta, mediated by activation of MEF2A and downregulation of class IIa HDACs. Oncogene 2010, 29:909-919.
55. Centrella M., McCarthy T.L., Canalis E. Activin-A binding and biochemical effects in osteoblast-enriched cultures from fetal-rat parietal bone. Mol Cell Biol 1991, 11:250-258.
56. Kawabata N., Kamiya N., Suzuki N., Matsumoto M., Takagi M. Changes in extracellular activin A:follistatin ratio during differentiation of a mesenchymal progenitor cell line, ROB-C26 into osteoblasts and adipocytes. Life Sci 2007, 81:8-18.
57. Vallet S., Mukherjee S., Vaghela N., Hideshima T., Fulciniti M., Pozzi S., et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A 2010, 107:5124-5129.
58. Chantry A.D., Heath D., Mulivor A.W., Pearsall S., Baud'huin M., Coulton L., et al. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J Bone Miner Res 2010, 25:2633-2646.
59. Hall C.L., Daignault S.D., Shah R.B., Pienta K.J., Keller E.T. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate 2008, 68:1396-1404.